The effect of AST/ALT (De Ritis) ratio on survival and its relation to tumor histopathological variables in patients with localized renal cell carcinoma

ABSTRACT

Purpose  To assess the relationship between De Ritis (aspartate aminotransaminase [AST]/Alanine aminotransaminase [ALT]) ratio and pathological variables and whether it is an independent prognostic factor.

Materials and Methods  We analyzed 298 consecutive patients who underwent radical or partial nephrectomy for non-metastatic renal cell carcinoma (RCC) between 2006 and 2015. The association between De Ritis ratio and pathological variables including tumor size, presence of renal vein invasion, vena cava invasion, renal capsule infiltration, Gerota fascia invasion, renal sinus involvement, renal pelvic invasion, angiolymphatic invasion, adrenal gland involvement, lymph node involvement, tumor necrosis, and Fuhrman's grade was tested. Multivariable Cox analysis was performed to evaluate the impact of this ratio on overall survival and cancer-specific survival.

Results  An increased preoperative De Ritis ratio was significantly associated with renal vein invasion, renal capsule infiltration and renal pelvis involvement (p<0.05) in non-metastatic RCC. On multivariate analysis we found that tumor size, Fuhrman grade and lymph node involvement were independent prognostic factors for cancer-specific survival. AST/ALT ratio had no influence on the risk of overall and cancer-specific survival.

Conclusion  An increased preoperative AST/ALT ratio had a significant association with renal vein invasion, renal capsule infiltration and renal pelvis involvement in patients with non-metastatic RCC. However, it does not appear to be an independent prognostic marker in non-metastatic RCC.

Keywords Prognosis; Survival; Pathology

INTRODUCTION

Renal cell carcinoma (RCC) accounts for 3% of all malignancies and thanks to advanced radiological tools, the incidence of RCC has increased during the last decade (¹, ²). It is important to research useful prognostic markers for the prognosis of RCC patients. Several prognostic parameters have been evaluated; stage, histologic type Fuhrman grade, several risk scores and nomograms remain crucial prognostic factors in RCC (³-⁵). Even though some of these prognostic models showed predictive accuracy, the correctness of prognostic factors should be demonstrated by novel research.

Aminotransaminases are expressed in several cellular compartments by malignant or nonmalignant cells. Alanine aminotransaminase (ALT) is only existent in the hepatocellular cytoplasm and mitochondria; however, aspartate aminotransaminase (AST) is widely spreaded in several organs, including heart, kidney, brain, skeletal muscle, and liver (⁶). The relationship between different levels of these enzymes and patient prognosis is stated in several types of cancer, previously (⁷-⁹).

Fernando De Ritis described the ratio of AST and ALT firstly, in 1957 and this ratio has been known ever since as the De Ritis ratio (¹⁰). Previous studies have demonstrated that this ratio to be crucial prognostic factors in different malignancies (¹¹-¹³). Bezan et al. and Lee et al. reported that this ratio can predict survival outcomes in patients with non-metastatic RCC and they found that an elevated AST/ALT ratio was significantly associated with inferior survival outcomes (¹⁴, ¹⁵). The aim of our study was to evaluate the effect of AST/ALT ratio on prognosis in our center and to investigate the relationship between this ratio and all histopathological variables in patients with surgically treated for non-metastatic RCC.

MATERIALS AND METHODS

In this retrospective analysis, the medical records of 412 patients who underwent radical or partial nephrectomy for non-metastatic RCC at our department between 2006 and 2015 were reviewed. The study was approved by the local committee of ethics and informed consents were obtained from eligible patients.

The databases included the basic demographic features, preoperative laboratory parameters, pathological findings and survival of patients. Plasma AST and ALT levels were analyzed by standard clinical methodology within 7 days prior to surgery. Pathological characteristics included tumor size, presence of renal vein invasion, vena cava invasion, renal capsule infiltration, Gerota fascia invasion, renal sinus involvement, renal pelvic invasion, tumor necrosis, angiolymphatic invasion, adrenal gland involvement, and lymph node involvement. Cellular grading was performed by Fuhrman's grading system (¹⁶) and staging was classified according to TNM 2010 classification (¹⁷). The pathological assessment was performed by an experienced pathologist.

Patients with distant metastasis (n=42) prior to treatment, patients with chronic hepatitis (n=9), other malignancies (n=8), pre-treatment or post-treatment chemotherapy, radiotherapy or immunotherapy (n=22), mixed type RCC or familial RCC (n=8), and incomplete information (n=25) were excluded from the study. The remaining 298 patients were included.

Postoperatively, every 6 months, all patients were assessed for the first 2 years and yearly thereafter. Cancer-specific survival (CSS) and overall survival (OS) rates were defined at the last follow-up date using surgery date to the date of cancer-specific mortality and any-cause of mortality. The pathological findings and their relation with the AST/ALT ratio were evaluated to determine which pathological parameters is affected by AST/ALT ratio. Since the optimum cut-off level of AST/ALT ratio of 1.5 had maximum Youden index value (¹², ¹⁵), we also analyzed the relationship between pathological parameters and high (AST/ALT≥1.5) or low (AST/ALT<1.5) levels of this ratio.

The data was analyzed with Statistical Package for Social Sciences (SPSS) version 22 (IBM Co., Armonk, NY, USA). Comparison between the AST/ALT ratio and several histopathological parameters was assessed by the Mann-Whitney U test and chi-square test. Univariate and multivariate logistic regression tests were used to analyze the associations between preoperative variables and adverse pathologic events. CSS and OS were estimated by Kaplan-Meier method with differences evaluated by log-rank test. Multivariate Cox proportional hazard analysis were performed to detect the effect of potential confounders, including age, tumor stage, and pathological variables. Correlations were considered statistically significant at a p<0.05 level.

RESULTS

The clinicopathological characteristics of all the patients are listed in Table-1. The patient's median age was 61 years (61.5±13.2) at surgery. 183 patients were male and 115 of them were female. The mean follow-up period was 37.8±22.3 months (17-54). Partial and radical nephrectomy was performed in 118 (39.6%) and 180 (60.4%), respectively. The histological cell types of RCC were clear cell in 210 patients (70.5%), papillary in 38 patients (12.7%), chromophobe in 24 patients (8.1%), collecting duct cell carcinoma in 5 patients (1.6%), and undifferentiated in 21 patients (7.1%). Distribution of tumor stage (I-II and III-IV) in this study was 222 (74.5%) and 76 (25.5%), respectively. Nuclear grading according to the Fuhrman classification was G1 in 18 (6.1%), G2 in 128 (42.9%), G3 in 78 (26.2%), G4 in 30 (10.1%), and undefined in 44 (14.7%). Median tumor size was 5cm (1.2-17.0cm) and median AST/ALT ratio was 1.1 (0.5-5.3).

Table 1
Clinicopathological characteristics of patients.

Characteristics		Min-Max	Median	Mean±s.d./n-%
Age		22-86	61	61.5±13.2
Sex
	Male			183-61.4%
	Female			115-38.6%
Histological type
	Clear cell			210-70.5%
	Papillary			38-12.7%
Chromophobe				24-8.1%
Collecting duct cell carcinoma				5-1.6%
Undifferentiated				21-7.1%
T Stage
I-II				222-74.50%
III-IV				76-25.50%
Fuhrman Grade
	I			18-6.1%
	II			128-42.9%
	III			78-26.2%
	IV			30-10.1%
	Undefined			44-14.7%
Tumor size (cm)		1.2-17.0	5.0	5.6±2.9
AST		10.0-85.0	19.0	21.8±10.7
ALT		5.0-96.0	17.0	21.5±14.8
AST/ALT		0.5-5.3	1.1	1.2±0.6

• AST = aspartate transaminase; ALT = alanine transaminase

Even though comparison of prognostic factors revealed several significant results on univariate analysis, AST/ALT ratio was not a prognostic factor for cancer-specific survival (p=0.293) and overall survival (p=0.456). On multivariate analysis we found that tumor size, Fuhrman grade and lymph node involvement were independent prognostic factors for CSS (Table-2).

Table 2
Univariate and multivariate Cox regression models of clinicopathological characteristics for the prediction of cancer specific survival.

	Univariate Model			Multivariate Model
	HR	%95 CI	p	HR	%95CI	p
Age	1.008	0.98 - 1.04	0.640
Sex	5.992	1.40 - 25.73	0.016
Histology type	0.490	0.21 - 1.16	0.106
Fuhrman Grade	3.546	2.03 - 6.20	0.000	2.730	1.56 - 4.79	0.000
Calcium	1.571	0.71 - 3.49	0.268
Hemoglobin	0.761	0.61 - 0.95	0.015
Tumor size	1.308	1.17 - 1.46	0.000	1.230	1.07 - 1.41	0.003
Renal vein invasion	4.966	1.44 - 17.09	0.011
Renal capsule infiltration	3.557	1.38 - 9.18	0.009
Renal sinüs involvement	4.836	2.04 - 11.49	0.000
Adrenal gland involvement	6.332	1.47 - 27.32	0.013
Gerota fascia invasion	35.738	3.99 - 319.8	0.001
Lymph node involvement	13.970	4.62 - 42.22	0.000	6.716	2.16 - 20.9	0.001
Angiolymphatic invasion	10.066	3.99 - 25.42	0.000
Renal pelvis involvement	2.957	1.08 - 8.09	0.035
AST	0.979	0.93 - 1.03	0.409
ALT	0.958	0.91 - 1.00	0.073
AST/ALT	1.306	0.79 - 2.15	0.293

• AST = aspartate transaminase; ALT = alanine transaminase; HR = hazard ratio

Analyzing AST/ALT ratio for any significant association with the histopathological variables, patients with renal vein invasion (n=18), renal capsule infiltration (n=34), and renal pelvis involvement (n=30) were found to have a significantly higher AST/ALT ratio (p=0.013, p=0.049, p=0.004, respectively). No other histopathological variable showed a significant association with AST/ALT ratio (Table-3). Regarding histopathological variables, patients in the high AST/ALT (AST/ALT≥1.5) group were more likely to have renal vein invasion (p=0.025), renal capsule infiltration (p=0.015), and renal pelvis involvement (p=0.001) compared with patients in the low AST/ALT (AST/ALT<1.5) group. Results of analysis showed that the level of AST/ALT was not associated with the tumor histological subtypes and pathological stage (Table-4).

Table 3
Association between AST/ALT ratio and histopathological variables.

		AST/ALT			P*
		Min-Mak	Medyan	Ort.±s.s.
Renal vein invasion	(-)	0.45 - 5.31	1.06	1.20 ± 0.58	0.013
	(+)	1.10 - 2.33	1.44	1.58 ± 0.41
Renal capsule infiltration	(-)	0.47 - 5.31	1.06	1.20 ± 0.58	0.049
	(+)	0.45 - 2.60	1.40	1.41 ± 0.54
Renal sinüs involvement	(-)	0.45 - 5.31	1.00	1.19 ± 0.59	0.079
	(+)	0.47 - 2.60	1.22	1.34 ± 0.53
Adrenal gland involvement	(-)	0.45 - 5.31	1.08	1.22 ± 0.58	0.749
	(+)	1.00 - 1.40	1.10	1.17 ± 0.21
Gerota fascia invasion	(-)	0.45 - 5.31	1.08	1.22 ± 0.58	0.505
	(+)	1.40 - 1.40	1.40	1.40 ±.
Lymph node involvement	(-)	0.45 - 5.31	1.07	1.22 ± 0.58	0.467
	(+)	0.79 - 2.00	1.33	1.36 ± 0.53
Angiolymphatic invasion	(-)	0.45 - 5.31	1.07	1.21 ± 0.59	0.355
	(+)	0.76 - 2.38	1.16	1.31 ± 0.52
Renal pelvis involvement	(-)	0.45 - 2.71	1.06	1.16 ± 0.46	0.004
	(+)	0.81 - 5.31	1.56	1.74 ± 1.08
Tumor necrosis	(-)	0.47 - 5.31	1.07	1.22 ± 0.60	0.726
	(+)	0.45 - 2.29	1.20	1.24 ± 0.50

• ^*
  Mann-Whitney u test, AST = aspartate transaminase; ALT = alanine transaminase

Table 4
Association of AST/ALT ratio with pathological parameters.

		AST/ALT≥1.5 n=80		AST/ALT<1.5 n=218		P
		n	%	n	%
Renal vein invasion		8	10	10	4.58	0.025
Renal capsule infiltration		16	20	18	8.25	0.015
Renal sinüs involvement		18	22.5	42	19.26	0.325
Adrenal gland involvement		2	2.5	6	2.75	0.438
Gerota fascia invasion		2	2.5	4	1.83	0.168
Lymph node involvement		4	5	8	3.66	0.315
Angiolymphatic invasion		10	12.5	26	11.92	0.521
Renal pelvis involvement		18	22.5	12	5.5	0.001
Tumor necrosis		14	17.5	32	14.67	0.425
Pathological stage						0.735
	I-II	56	70	166	76.2
	III-IV	24	30	52	23.8
Fuhrman grade						0.065
	I	4	5	14	6.4
	II	34	42.5	94	43.11
	III	24	30	54	24.7
	IV	12	10	18	8.25
Histological type						0.455
	Clear-cell	58	72.5	152	69.7
	Papillary	9	11.2	29	13.3
Chromophobe		6	7.5	18	8.2
Collecting duct cell carcinoma		2	2.5	3	1.3
Undifferentiated		5	6.2	16	7.3

• AST = aspartate transaminase; ALT = alanine transaminase

DISCUSSION

Although the De Ritis ratio was not associated with overall and cancer-specific survival for non-metastatic RCC in the present study, we found that patients with the high AST/ALT ratio were more likely to have renal vein invasion, renal capsule infiltration, and renal pelvis involvement compared with patients in the low AST/ALT ratio. We also found that tumor size, Fuhrman grade and lymph node involvement were independent prognostic factors in patients with non-metastatic RCC.

Plasma AST level and AST/ALT ratio were defined previously as a convenient markers for hepatocellular carcinoma and they were associated with poor prognosis (¹⁸, ¹⁹). Additionally, some previous studies have demonstrated that this ratio to be a significant prognostic factor in several malignancies (¹¹, ¹², ²⁰, ²¹). Recently, two similar studies reported that an elevated AST/ALT ratio was significantly associated with poor survival outcomes which were not in line with our results (¹⁴, ¹⁵). Moreover, the previous studies were lacking the evaluation of the association of AST/ALT ratio with detailed histopathological variables. Up to our study, there were no other study focusing on the relationships between De Ritis ratio and a comprehensive histopathological analysis in the evaluable literature.

While ALT is considered more liver specific, AST is present in many tissue types. The functions of both these enzymes represent crucial metabolic interactions between protein and carbohydrate metabolism. They are also important in all cells that have a high metabolic activity and AST is even more vital for aerobic glycolysis (⁶). Hsu and Sabatini reported that malignant cells show a higher rate of aerobic glycolysis than nonmalignant cells (²²). Von Hippel-Lindau (VHL) gene is known to be the most frequent mutation in RCC which is connected to increased glycolysis (²³). It may be explained that AST is involved in the glycolysis pathway in RCC with the lack of a functional VHL gene. The VHL gene mutation in clear cell RCC plays an important role in activate HIF/VEGF pathway. However, our results showed that the tumor histological subtypes were not associated with AST/ALT ratio.

In our study, elevated AST/ALT ratio in the preoperative period was associated with renal vein invasion. Venous invasion is a poor prognostic factor and these tumors are associated with poor survival rates (²⁴, ²⁵). Regarding CT staging of segmental or main renal vein invasion, sensitivity of 59-69% have been reported (²⁶). Therefore, there is a requirement for predicting the probability of renal vein invasion with new markers. AST/ALT ratio may be considered a valid biomarker for the prediction of renal vein invasion in decision making of the management of disease.

RCCs generally do not have a true histologic capsule, but are surrounded by a pseudo-capsule. Pseudo-capsule formation is the result of tumor growth and necrosis of the adjacent renal parenchyma (²⁷). Jeong et al. reported that capsular infiltration appears to have a poor prognosis than those with equivalently staged RCC without capsular infiltration (²⁸). A pseudo-capsule was detected in 26% of neoplasms on CT, in 67% of neoplasms on angiography, and in 93% of tumors on T2-weighted sequences on magnetic resonance imaging (²⁹). For this reason, preoperative AST/ALT ratio may be a good marker for predicting renal capsular infiltration in non-metastatic RCC.

Terrone et al. reported that urinary collecting system involvement does not affect the outcome of RCC in an independent manner; however, in organ-confined tumors urinary collecting system involvement should be taken into account when planning treatments (³⁰). We also found that renal pelvis involvement was not an independent prognostic factor for cancer-specific survival in RCC. Moreover, we demonstrated that renal pelvis involvement was associated with elevated AST/ALT ratio. This ratio should be taken into account when planning especially partial nephrectomy and follow-up.

Limitations of our study are the retrospective design with relatively few patients and the limited follow-up. Before the De Ritis ratio can be applied generally, it must be validated in large, prospective studies.

CONCLUSIONS

An increased De Ritis ratio had a significant association with renal vein invasion, renal capsule infiltration and renal pelvis involvement in patients with non-metastatic RCC. Despite the relationship, this ratio did not represent an independent prognostic factor with respect to overall and cancer-specific survival in patients with non-metastatic RCC.

• Published as Ahead of Print: November 17, 2017

ABBREVIATIONS
• RCC  renal cell carcinoma
• ALT  alanine aminotransaminase
• AST  aspartate aminotransaminase
• OS  overall survival
• CSS  cancer specific survival
• VHL  Von Hippel-Lindau

REFERENCES

• ¹ Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612-24.
• ² Weikert S, Ljungberg B. Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. World J Urol. 2010;28:247-52.
• ³ Ficarra V, Righetti R, Pilloni S, D'amico A, Maffei N, Novella G, et al. Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol. 2002;41:190-8.
• ⁴ Cindolo L, Patard JJ, Chiodini P, Schips L, Ficarra V, Tostain J, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer. 2005;104:1362-71.
• ⁵ Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Rehak P, et al. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol. 2011;186:1773-7.
• ⁶ Botros M, Sikaris KA. The de ritis ratio: the test of time. Clin Biochem Rev. 2013;34:117-30.
• ⁷ Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer. 1990;61:597-604. Erratum in: Br J Cancer 1990;62:550.
• ⁸ Tan X, Xiao K, Liu W, Chang S, Zhang T, Tang H. Prognostic factors of distal cholangiocarcinoma after curative surgery: a series of 84 cases. Hepatogastroenterology. 2013;60:1892-5.
• ⁹ van der Gaast A, Verweij J, Planting AS, Hop WC, Stoter G. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol. 1995;13:1720-5.
• ¹⁰ De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta. 1957;2:70-4.
• ¹¹ Takenaka Y, Takemoto N, Yasui T, Yamamoto Y, Uno A, Miyabe H, et al. Transaminase Activity Predicts Survival in Patients with Head and Neck Cancer. PLoS One. 2016;11:e0164057.
• ¹² Lee H, Choi YH, Sung HH, Han DH, Jeon HG, Chang Jeong B, et al. De Ritis Ratio (AST/ALT) as a Significant Prognostic Factor in Patients With Upper Tract Urothelial Cancer Treated With Surgery. Clin Genitourin Cancer. 2017;15:e379-e385.
• ¹³ Lin CS, Chang CS, Yang SS, Yeh HZ, Lin CW. Retrospective evaluation of sérum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma. Intern Med. 2008;47:569-75.
• ¹⁴ Bezan A, Mrsic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R, et al. The Preoperative AST/ALT (De Ritis) Ratio Represents a Poor Prognostic Factor in a Cohort of Patients with Nonmetastatic Renal Cell Carcinoma. J Urol. 2015;194:30-5.
• ¹⁵ Lee H, Lee SE, Byun SS, Kim HH, Kwak C, Hong SK. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study. BJU Int. 2017;119:261-7.
• ¹⁶ Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-63.
• ¹⁷ Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Groselj-Strele A, et al. Predictive ability of the 2002 and 2010 versions of the Tumour-Node-Metastasis classification system regarding metastasis-free, cancer-specific and overall survival in a European renal cell carcinoma single-centre series. BJU Int. 2013;111(4 Pt B):E191-5.
• ¹⁸ Wang ZX, Jiang CP, Cao Y, Zhang G, Chen WB, Ding YT. Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015;14:178-85.
• ¹⁹ Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, et al. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS One. 2013;8:e61448.
• ²⁰ Stocken DD, Hassan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ, et al. Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer. 2008;99:883-93.
• ²¹ Chougule A, Hussain S, Agarwal DP. Prognostic and diagnostic value of sérum pseudocholinesterase, serum aspartate transaminase, and serum alinine transaminase in malignancies treated by radiotherapy. J Cancer Res Ther. 2008;4:21-5.
• ²² Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134:703-7.
• ²³ Sudarshan S, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, et al. Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol. 2013;63:244-51.
• ²⁴ Ball MW, Gorin MA, Harris KT, Curtiss KM, Netto GJ, Pavlovich CP, et al. Extent of renal vein invasion influences prognosis in patients with renal cell carcinoma. BJU Int. 2016;118:112-7.
• ²⁵ Martínez-Salamanca JI, Huang WC, Millán I, Bertini R, Bianco FJ, Carballido JA, et al. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol. 2011;59:120-7.
• ²⁶ Sokhi HK, Mok WY, Patel U. Stage T3a renal cell carcinoma: staging accuracy of CT for sinus fat, perinephric fat or renal vein invasion. Br J Radiol. 2015;88(1045):20140504.
• ²⁷ Minervini A, di Cristofano C, Lapini A, Marchi M, Lanzi F, Giubilei G, et al. Histopathologic analysis of peritumoral pseudocapsule and surgical margin status after tumor enucleation for renal cell carcinoma. Eur Urol. 2009;55:1410-8.
• ²⁸ Jeong IG, Jeong CW, Hong SK, Kwak C, Lee E, Lee SE. Prognostic implication of capsular invasion without perinephric fat infiltration in localized renal cell carcinoma. Urology. 2006;67:709-12.
• ²⁹ Takahashi S, Ueda J, Furukawa T, Higashino K, Tsujihata M, Itatani H, et al. Renal cell carcinoma: preoperative assessment for enucleative surgery with angiography, CT, and MRI. J Comput Assist Tomogr. 1996;20:863-70.
• ³⁰ Terrone C, Cracco C, Guercio S, Bollito E, Poggio M, Scoffone C, et al. Prognostic value of the involvement of the urinary collecting system in renal cell carcinoma. Eur Urol. 2004;46:472-6.

Publication Dates

• Publication in this collection
  Mar-Apr 2018

History

• Received
  22 Mar 2017
• Accepted
  17 June 2017